BioNTech’s Oncology Pivot Nears a Critical Test as ASCO Looms and Restructuring Takes Hold

BioNTech to unveil pumitamig Phase 2 lung cancer data at ASCO; cost-cutting targets €500M annual savings; €16.8B cash; BMS deal worth up to $7.6B.

The next major judgment on BioNTech’s cancer-focused reinvention arrives in late May, when the company unveils Phase 2 data for its flagship bispecific immunotherapy, pumitamig, at the ASCO conference. The readout comes from a lung-cancer study that pits the drug directly against pembrolizumab, and its outcome will either validate a multi-billion-dollar strategic gamble or leave the market waiting longer for proof.

Shareholders have already given management a clear mandate to push ahead. At the virtual annual general meeting on May 15, 92% of the share capital was represented, and all agenda items passed comfortably. The board was expanded from six to eight seats, with two new independent members: Iris Löw-Friedrich, an expert in clinical development, and Susanne Schaffert, formerly of Merck KGaA. Helmut Jeggle took the chair, while incumbents Anja Morawietz and Rudolf Staudigl had their mandates renewed. The composition underlines a singular focus: oncology expertise at the top.

The operational pivot is running in parallel with a painful cost-cutting drive. BioNTech plans to shutter production sites in Idar-Oberstein, Marburg and Singapore, and will also consolidate facilities linked to the former CureVac collaboration. Around 1,860 employees are affected, though management has promised socially responsible solutions. Ugur Sahin, the CEO, acknowledged the responsibility to staff, even as he and research chief Özlem Türeci prepare to step down at the end of 2026.

Annual savings of roughly €500 million are targeted by 2029. That discipline is necessary because the COVID-era revenue boom has faded. For 2025, BioNTech reported sales of €2.87 billion, ahead of its own forecast, but the outlook for 2026 is more modest: €2.0 billion to €2.3 billion. Research and development spending, excluding adjustments, is guided at €2.2 billion to €2.5 billion, underscoring how the company is funding its cancer ambitions from a strong balance sheet rather than near-term product income.

That balance sheet is indeed formidable. At the end of the first quarter of 2026, BioNTech held €16.8 billion in cash, cash equivalents and securities. The AGM also authorised a new share buyback programme of up to $1 billion over the next 12 months — a signal that management sees value in its own stock — while no dividend was proposed. Additionally, shareholders approved a new authorised capital plan (Authorised Capital 2026), covering up to half of the existing share capital, and a control and profit transfer agreement for BioNTech Discovery GmbH that will allow the group to offset profits against losses for tax efficiency.

The most important non-financial item, however, is the partnership with Bristol Myers Squibb on pumitamig. The US pharma giant paid $1.5 billion upfront, with a further $2 billion in unconditional payments scheduled through 2028. If the drug hits all its milestones, BioNTech could receive up to $7.6 billion more. Sahin described pumitamig as the company’s flagship and said it has shown activity across multiple tumour types. With more than 25 late-stage studies running and 17 clinical programmes in total, the pipeline now includes data from over 4,000 patients.

Investors have held back, however. The stock closed at €77.10 on Friday, down 2.03% and well below its 200-day moving average of €86.94. Analyst opinions remain split: 15 of 19 tracked analysts rate the shares a strong buy, while four hold; price targets range from $94 to $171. Berenberg trimmed its target on May 12 but still described the stock as significantly undervalued.

The wide valuation spread reflects the binary nature of the next catalyst. Pumitamig’s performance at ASCO will be the first rigorous external test of whether BioNTech’s transformation from vaccine maker to oncology powerhouse is clinically convincing. Until the data speaks, the €16.8 billion cash pile remains as much a shield against fading COVID-era revenues as it is a springboard for the future.